KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Asset Writedowns and Impairment (2016 - 2025)

NovoCure's Asset Writedowns and Impairment history spans 12 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 416.27% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $4.9 million, up 318.55%, while the annual FY2025 figure was $4.9 million, 318.55% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $1.9 million at NovoCure, up from $230000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.3 million in Q1 2025 and bottomed at $112000.0 in Q3 2023.
  • The 5-year median for Asset Writedowns and Impairment is $180000.0 (2021), against an average of $405350.0.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 2833.33% in 2021 before it crashed 73.02% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $182000.0 in 2021, then soared by 142.31% to $441000.0 in 2022, then plummeted by 73.02% to $119000.0 in 2023, then soared by 215.13% to $375000.0 in 2024, then soared by 416.27% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Asset Writedowns and Impairment are $1.9 million (Q4 2025), $230000.0 (Q3 2025), and $424000.0 (Q2 2025).